FDA approves new antibiotic for skin infections

Published



WASHINGTON (AP) — The Food and Drug Administration has approved a new antibiotic from Durata Therapeutics to treat adults with common skin infections often acquired in U.S. hospitals.

Regulators approved the intravenous drug Dalvance to treat bacterial skin infections caused by common bacteria, including antibiotic-resistant strains of those germs.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.